By Iain Gilbert
Date: Friday 27 Mar 2026
(Sharecast News) - Drugmaker AstraZeneca said on Friday that its monoclonal antibody tozorakimab had met the primary endpoint in both of its Phase III OBERON and TITANIA trials in patients with chronic obstructive pulmonary disease.
| Tozorakimab met OBERON/TITANIA primary endpoints | 27-Mar-2026 | 07:00 | RNS |
| Notification of Admission of Shares | 20-Mar-2026 | 11:00 | RNS |
| Imfinzi approved in EU for early gastric cancer | 16-Mar-2026 | 07:00 | RNS |
| Imfinzi approved in EU for early gastric cancer | 16-Mar-2026 | 07:00 | RNS |
| Notice of AGM | 10-Mar-2026 | 11:00 | RNS |
| Questor :AstraZeneca | 29-Apr-2014 | Telegraph |
| Questor : AstraZeneca | 24-Jan-2014 | Telegraph |
| Questor:AstraZeneca | 22-Dec-2011 | Telegraph |
| Investment Column:AstraZeneca | 28-Oct-2011 | The Independent |
| Investment Column: AstraZeneca | 23-Jun-2011 | The Independent |
| Currency | UK Pounds |
| Share Price | 14,302.00p |
| Change Today | 472.00p |
| % Change | 3.41 % |
| 52 Week High | 15,252.00 |
| 52 Week Low | 9,667.00 |
| Volume | 2,660,473 |
| Shares Issued | 1,550.97m |
| Market Cap | £221,819m |
| Beta | 0.00 |
| RiskGrade | 123 |
| Value |
|
|---|
| Price Trend |
|
|---|
| Income |
|
|---|
| Growth |
|
|---|
| Strong Buy | 10 |
| Buy | 13 |
| Neutral | 3 |
| Sell | 0 |
| Strong Sell | 1 |
| Total | 27 |

| Latest | Previous | |
|---|---|---|
| 2nd Interim | 1st Interim | |
| Ex-Div | 19-Feb-26 | 07-Aug-25 |
| Paid | 23-Mar-26 | 08-Sep-25 |
| Amount | 217.00¢ | 103.00¢ |
| Time | Volume / Share Price |
| 15:46 | 0 @ 14,332.00p |
| 15:46 | 0 @ 14,332.00p |
| 15:46 | 0 @ 14,332.00p |
| 15:32 | 1 @ 14,332.00p |
| 15:19 | 0 @ 14,310.00p |
You are here: research